DUAL-REGISTERED PROTOCOL // OSF PRE-REGISTERED (DOI: 10.17605/OSF.IO/VPS9D) · CLINICALTRIALS.GOV PRS IN PROGRESS · PROTOCOL ID: DS-CLIN-2026-MIND-RESOLVE · PLANNED N = 10,000
MIND-RESOLVE™ Registry.
Rescuing treatment-resistant depression via systems biology.
Over 30% of major depressive disorder patients fail two or more lines of antidepressant therapy, trapped in diagnostic silos while underlying neuroinflammation, tryptophan-kynurenine diversion, and gut-microbiome metabolic failure remain ignored. MIND-RESOLVE™ is a global decentralized clinical registry ($N=10,000$) uniting the DeepSensi Cognitive Engine with multi-system immuno-metabolic tensors. Participation in the registry is 100% Free.
RESOLVE in the United States: in preparation (IRB submission in preparation, the first country to open).
Core DeepSensi Specialization
Difficult Cases, Cross-Domain Systems Biology & The "Inter-Specialty White Space"
Why the Brain Does Not Live in an Anatomical Vacuum
Psychiatry has operated as the most isolated specialty in modern medicine, assuming mood disorders are merely monoamine transmitter deficits. In reality, refractory depression is frequently the neurological downstream manifestation of systemic metabolic and immunological breakdown. DeepSensi operates in the inter-specialty white space connecting gastroenterology, endocrinology, neuroimmunology, and cellular bioenergetics to resolve root causes: microglial hyperactivation, kynurenine-driven quinolinic acid excitotoxicity, insulin-resistant neuronal energy starvation, and occult autoimmune encephalitis.
Registry Strata
Three Specialized Psychiatric Cohorts
Treatment-Resistant Depression (TRD)
Major depressive disorder patients failing ≥ 2 sequential antidepressant trials with adequate dose and duration. Mapping quinolinic acid / kastle-meyer ratios, cerebral glucose hypometabolism, and systemic inflammatory biotypes (hs-CRP ≥ 3 mg/L).
Neuroinflammatory & Autoimmune Mood Disorders
Bipolar spectrum, rapid cycling, and acute-onset mood disorders with low-titer antineuronal antibodies (NMDA, CASPR2, LGI1, thyroid peroxidase TPO) and cytokine storm signatures refractory to standard mood stabilizers.
Microbiome-Gut-Brain Axis & Post-Viral Collapse
Severe anhedonia, brain fog, and chronic affective blunting post-infection (Long COVID, EBV, Lyme). Decoupling vagal nerve signaling deficits, short-chain fatty acid (SCFA) exhaustion, and clostridial metabolite neurotoxicity.
From routine care, ordered by each participant's own physicians, the registry also records urine organic acids and a metagenomic stool profile, through which it observes the gut-brain axis, together with medicine levels and the pharmacogenomic report where available.
Clinical Endpoints
Validated Primary & Mechanistic Endpoints
MADRS & QIDS-SR16 Score Reduction
Achievement of clinical remission (MADRS ≤ 10) and ≥ 50% symptom reduction sustained across 12 months without polypharmacy toxicity or cognitive blunting.
Kynurenine / Tryptophan Ratio Normalization
De-escalation of neurotoxic quinolinic acid pathway activation, normalization of systemic IL-6 and TNF-α, and restoration of neuroprotective kynurenic acid balance.
Continuous Circadian & HRV Restoration
Restoration of slow-wave sleep (SWS) architecture and vagal heart rate variability (HRV RMSSD) tracked continuously via passive wearable biosensors.
Join the MIND-RESOLVE™ Registry
Are you a psychiatrist seeking root-cause precision tools for non-responding patients, or an individual navigating treatment-resistant depression? Participation in our global DCT registry is 100% free.
DeepSensi DCT
